Medicaid Drug Utilization Review (DUR) Board Meeting Agenda for November 12, 2009

The Drug Utilization Review (DUR) Board will meet November 12, 2009, from 9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

The Board will deliberate on Medicaid pharmacy initiatives and processes relating to appropriate, medically necessary prescribing and medical standards and criteria for the retrospective and prospective Drug Utilization Review program.

Agenda Items:

  1. Medication Therapy Management (MTM) Program Update
  2. Prescriber Education Program (PEP) Update
  3. Psychiatric Services and Clinical Knowledge Enhancement System (PSYCKES) Update
  4. Medicaid DUR Activities Report
  5. Drug utilization presentations and discussion of the following drugs/drug classes:
  • Oral Bisphosphonates
    • Drugs Affected:
      • Actonel (risedronate), Actonel with Calcium (risedronate with calcium carbonate), alendronate, Boniva (ibandronate), Fosamax (alendronate), Fosamax Plus D (alendronate plus cholecalciferol)
  • Inhaled Corticosteroids
    • Drugs Affected:
      • Advair Diskus (fluticasone/salmeterol), Advair HFA (fluticasone/salmeterol), Aerobid/Aerobid-M (flunisolide), Alvesco (ciclesonide), Asmanex (mometasone), Azmacort (triamcinolone), Flovent Diskus (fluticasone), Flovent HFA (fluticasone), Pulmicort Flexhaler (budesonide), QVAR (beclomethasone), Symbicort (budesonide/formoterol)
  • Nasal Corticosteroids
    • Drugs Affected:
      • Beconase AQ (beclomethasone dipropionate), Flonase (fluticasone propionate), flunisolide, fluticasone propionate, Nasacort AQ (triamcinolone acetonide), Nasarel (flunisolide), Nasonex (mometasone furoate), Omnaris (ciclesonide), Rhinocort Aqua (budesonide), Veramyst (fluticasone furoate)
  • Diclofenac Gel (Solaraze)
  • Becaplermin (Regranex)
  • Tramadol
    • Drugs Affected:
      • Ultram, Ultram ER, Ryzolt
  • Ophthalmic Fluoroquinolones
    • Drugs Affected:
      • Besivance (besifloxacin), Ciloxan (ciprofloxacin), ciprofloxacin, IQUIX (levofloxacin), Ocuflox (ofloxacin), ofloxacin, Quixin (levofloxacin), Vigamox (moxifloxacin), Zymar (gatifloxacin)

Agenda Timeline (subject to change based on meeting proceedings)

Time Agenda Topic
9:00 - 9:15 Welcome and Introductions
9:15 - 10:15 Public Comment Period*
10:15 - 10:30 Medication Therapy Management (MTM) Program Update
10:30 - 10:45 Prescriber Education Program (PEP) Update
10:45 - 11:00 Break
11:00 - 11:15 Psychiatric Services and Clinical Knowledge Enhancement System (PSYCKES) Update
11:15 - 11:45 Medicaid DUR Activities Report
11:45 - 12:15 Becaplermin Presentation and Discussion of Utilization
12:15 - 1:30 Lunch - Executive Session
1:30 - 1:50 Oral Bisphosphonate Presentation and Discussion of Utilization
1:50 - 2:10 Inhaled and Nasal Corticosteroid Presentation and Discussion of Utilization
2:10 - 2:30 Diclofenac Presentation and Discussion of Utilization
2:30 - 2:45 Break
2:45 - 3:30 Tramadol Presentation and Discussion of Utilization
3:30 - 4:15 Ophthalmic Fluroquinolone Presentation and Discussion of Utilization
4:15 - 4:30 Final Comments/Adjournment

*Interested parties must notify the Drug Utilization Review Manager at least one (1) week prior to the meeting of their request to address the Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference DUR Board). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed 60 minutes. All written statements up to two (2) pages in length may be received up to one (1) week in advance of the meeting. These statements should summarize key points.

NOTE: Those wishing to submit information greater than two (2) pages in length for DUR Board consideration must do so at least two (2) weeks prior to the date of the meeting, or the Board may not have ample time to review the information.

Posted 10/20/2009